MedTrace Logo

Study on Risk Factors and Prognostic Value of Non-target Lesion Progression in Patients With Coronary Artery Disease

NCT07748754 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1400

Last updated 2026-08-06

No results posted yet for this study

Summary

The goal of this observational study is to explore the risk factors and prognostic value of non-target coronary lesion progression in patients aged 18-80 years with established coronary artery disease who are scheduled for repeat coronary angiography. The main questions it aims to answer are:

What clinical, inflammatory and metabolic factors are independently associated with the progression of untreated non-target lesions after percutaneous coronary intervention? Does the initial interventional strategy (drug-eluting stent vs. drug-coated balloon) influence the long-term progression of non-target coronary lesions and subsequent clinical outcomes? Researchers will compare participants treated with drug-eluting stents (DES) and those treated with drug-coated balloons (DCB) at their prior index procedure to see if different local interventional modalities lead to differences in non-target lesion progression and major adverse cardiovascular events during follow-up.

Participants will:

Undergo clinically indicated repeat coronary angiography, with offline quantitative coronary angiography (QCA) analysis of all coronary segments Provide baseline clinical data, medical history and blood samples for inflammatory and metabolic biomarker testing Complete 3 years of regular clinical follow-up to track lesion evolution and cardiovascular endpoints

Conditions

  • Coronary Artery Disease (CAD)

Interventions

OTHER

Progression of non-target vessels

Drug-eluting stents (DES) have markedly reduced the risks of target lesion restenosis and repeat revascularization \[2\]. Nevertheless, the progression of coronary atherosclerosis does not cease after percutaneous coronary intervention (PCI). Clinical evidence demonstrates that even after successful target lesion revascularization and adherence to standardized secondary prevention therapy, patients may still develop progression of non-target lesions (NTLs) during follow-up, which further leads to non-target vessel revascularization, recurrent myocardial infarction, and major adverse cardiovascular events (MACE) \[3\]. This finding indicates that post-PCI risk is not solely driven by severely stenotic target lesions; to a certain extent, it may also arise from initially untreated non-target lesions that harbor progression potential. This issue has become one of the key factors limiting the long-term clinical benefit of patients with coronary artery disease following interventional therapy.

Sponsors & Collaborators

  • Beijing Anzhen Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2026-08-01
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07748754 on ClinicalTrials.gov